2022
Abnormal left atrial body stiffness is predicted by appendage size: impact of appendage occlusion on left atrial mechanics assessed by pressure-volume analysis
Bregasi A, Freeman JV, Curtis JP, Akar JG, Ortiz-Leon XA, Maia JH, Higgins AY, Matthews RV, Sinusas AJ, McNamara RL, Sugeng L, Lin BA. Abnormal left atrial body stiffness is predicted by appendage size: impact of appendage occlusion on left atrial mechanics assessed by pressure-volume analysis. AJP Heart And Circulatory Physiology 2022, 323: h559-h568. PMID: 35960632, PMCID: PMC9576173, DOI: 10.1152/ajpheart.00083.2022.Peer-Reviewed Original ResearchConceptsLeft atrial appendage occlusionLA stiffnessAppendage occlusionLA appendageLA mechanicsTransesophageal echocardiographyPressure-volume analysisPercutaneous left atrial appendage occlusionAdverse atrial remodelingAtrial appendage occlusionLeft atrial appendageLA volume measurementsAtrial cardiomyopathyBaseline characteristicsLA complianceAtrial remodelingClinical outcomesAtrial appendageAtrial mechanicsCardiac performancePathophysiological roleBaseline parametersMagnitude of increaseAppendage sizeOcclusion
2006
Anticoagulants or antiplatelet therapy for non‐rheumatic atrial fibrillation and flutter
Segal J, McNamara R, Miller M, Powe N, Goodman S, Robinson K, Bass E. Anticoagulants or antiplatelet therapy for non‐rheumatic atrial fibrillation and flutter. 2006, 2010: cd001938. PMID: 17636690, PMCID: PMC10759270, DOI: 10.1002/14651858.cd001938.pub2.Peer-Reviewed Original ResearchConceptsAggregate odds ratioRisk of hemorrhageAtrial fibrillationStroke preventionMajor hemorrhageOdds ratioDose warfarinMajor bleedsModerate evidenceCochrane Collaboration's CENTRAL databaseNon-postoperative atrial fibrillationNon-rheumatic atrial fibrillationLow molecular weight heparinAdditional major bleedsLow-dose warfarinMore major bleedingMore major bleedsMore major hemorrhageRCTs of patientsPrimary stroke preventionLow-risk patientsRheumatic valvular diseasePrevention of thromboembolismRisk of strokeTrials of drugs
2001
Anticoagulants or antiplatelet therapy for non‐rheumatic atrial fibrillation and flutter
Segal J, McNamara R, Miller M, Powe N, Goodman S, Robinson K, Bass E. Anticoagulants or antiplatelet therapy for non‐rheumatic atrial fibrillation and flutter. Cochrane Database Of Systematic Reviews 2001, cd001938. PMID: 11279741, DOI: 10.1002/14651858.cd001938.Peer-Reviewed Original ResearchConceptsRisk of hemorrhageAtrial fibrillationStroke preventionMajor hemorrhageDose warfarinMajor bleedsOdds ratioModerate evidenceCochrane Collaboration's CENTRAL databaseNon-postoperative atrial fibrillationNon-rheumatic atrial fibrillationLow molecular weight heparinAdditional major bleedsAggregate odds ratioLow-dose warfarinMore major bleedingMore major bleedsMore major hemorrhageRCTs of patientsPrimary stroke preventionLow-risk patientsRheumatic valvular diseasePrevention of thromboembolismRisk of strokeTrials of drugs
2000
Distribution, Severity and Risk Factors for Aortic Atherosclerosis in Cerebral Ischemia
Sen S, Wu K, McNamara R, Lima J, Piantadosi S, Oppenheimer S. Distribution, Severity and Risk Factors for Aortic Atherosclerosis in Cerebral Ischemia. Cerebrovascular Diseases 2000, 10: 102-109. PMID: 10686448, DOI: 10.1159/000016038.Peer-Reviewed Original ResearchConceptsRisk factorsAortic atheromaAortic plaquesCarotid stenosisStroke/TIA patientsSymptomatic coronary artery diseaseAortic plaque thicknessThoracic aortic plaqueTransesophageal echocardiography assessmentIndependent risk factorCoronary artery diseaseIschemic heart diseaseExtracranial carotid stenosisTIA patientsAortic atherosclerosisAsymptomatic patientsIschemic strokeArtery diseaseCerebral ischemiaConsecutive patientsEchocardiography assessmentMultivariable analysisProximal aortaCardiac screeningHeart disease